Genome-scale CRISPR-Cas9 knockout screening in human cells O Shalem, NE Sanjana, E Hartenian, X Shi, DA Scott, TS Mikkelsen, ... Science 343 (6166), 84-87, 2014 | 5840 | 2014 |
Optimized sgRNA design to maximize activity and minimize off-target effects of CRISPR-Cas9 JG Doench, N Fusi, M Sullender, M Hegde, EW Vaimberg, KF Donovan, ... Nature biotechnology 34 (2), 184-191, 2016 | 4237 | 2016 |
Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1 DA Barbie, P Tamayo, JS Boehm, SY Kim, SE Moody, IF Dunn, ... Nature 462 (7269), 108-112, 2009 | 3340 | 2009 |
A next generation connectivity map: L1000 platform and the first 1,000,000 profiles A Subramanian, R Narayan, SM Corsello, DD Peck, TE Natoli, X Lu, ... Cell 171 (6), 1437-1452. e17, 2017 | 2865 | 2017 |
Defining a cancer dependency map A Tsherniak, F Vazquez, PG Montgomery, BA Weir, G Kryukov, ... Cell 170 (3), 564-576. e16, 2017 | 2369 | 2017 |
lincRNAs act in the circuitry controlling pluripotency and differentiation M Guttman, J Donaghey, BW Carey, M Garber, JK Grenier, G Munson, ... Nature 477 (7364), 295-300, 2011 | 2203 | 2011 |
A lentiviral RNAi library for human and mouse genes applied to an arrayed viral high-content screen J Moffat, DA Grueneberg, X Yang, SY Kim, AM Kloepfer, G Hinkle, ... Cell 124 (6), 1283-1298, 2006 | 2059 | 2006 |
Rational design of highly active sgRNAs for CRISPR-Cas9–mediated gene inactivation JG Doench, E Hartenian, DB Graham, Z Tothova, M Hegde, I Smith, ... Nature biotechnology 32 (12), 1262-1267, 2014 | 1849 | 2014 |
COT drives resistance to RAF inhibition through MAP kinase pathway reactivation CM Johannessen, JS Boehm, SY Kim, SR Thomas, L Wardwell, ... Nature 468 (7326), 968-972, 2010 | 1750 | 2010 |
Functional genomics reveal that the serine synthesis pathway is essential in breast cancer R Possemato, KM Marks, YD Shaul, ME Pacold, D Kim, K Birsoy, ... Nature 476 (7360), 346-350, 2011 | 1720 | 2011 |
Computational correction of copy number effect improves specificity of CRISPR–Cas9 essentiality screens in cancer cells RM Meyers, JG Bryan, JM McFarland, BA Weir, AE Sizemore, H Xu, ... Nature genetics 49 (12), 1779-1784, 2017 | 1701 | 2017 |
Identification of RPS14 as a 5q- syndrome gene by RNA interference screen BL Ebert, J Pretz, J Bosco, CY Chang, P Tamayo, N Galili, A Raza, ... Nature 451 (7176), 335-339, 2008 | 1100 | 2008 |
In vivo CRISPR screening identifies Ptpn2 as a cancer immunotherapy target RT Manguso, HW Pope, MD Zimmer, FD Brown, KB Yates, BC Miller, ... Nature 547 (7664), 413-418, 2017 | 1085 | 2017 |
The JAK2/STAT3 signaling pathway is required for growth of CD44+CD24– stem cell–like breast cancer cells in human tumors LLC Marotta, V Almendro, A Marusyk, M Shipitsin, J Schemme, SR Walker, ... The Journal of clinical investigation 121 (7), 2723-2735, 2011 | 1002 | 2011 |
β-Catenin-driven cancers require a YAP1 transcriptional complex for survival and tumorigenesis J Rosenbluh, D Nijhawan, AG Cox, X Li, JT Neal, EJ Schafer, TI Zack, ... Cell 151 (7), 1457-1473, 2012 | 846 | 2012 |
CDK8 is a colorectal cancer oncogene that regulates β-catenin activity R Firestein, AJ Bass, SY Kim, IF Dunn, SJ Silver, I Guney, E Freed, ... Nature 455 (7212), 547-551, 2008 | 817 | 2008 |
Subtype-specific genomic alterations define new targets for soft-tissue sarcoma therapy J Barretina, BS Taylor, S Banerji, AH Ramos, M Lagos-Quintana, ... Nature genetics 42 (8), 715-721, 2010 | 811 | 2010 |
(R)-2-Hydroxyglutarate Is Sufficient to Promote Leukemogenesis and Its Effects Are Reversible JA Losman, RE Looper, P Koivunen, S Lee, RK Schneider, C McMahon, ... Science 339 (6127), 1621-1625, 2013 | 792 | 2013 |
Optimized libraries for CRISPR-Cas9 genetic screens with multiple modalities KR Sanson, RE Hanna, M Hegde, KF Donovan, C Strand, ME Sullender, ... Nature communications 9 (1), 5416, 2018 | 787 | 2018 |
KRAS and YAP1 converge to regulate EMT and tumor survival DD Shao, W Xue, EB Krall, A Bhutkar, F Piccioni, X Wang, AC Schinzel, ... Cell 158 (1), 171-184, 2014 | 776 | 2014 |